WEBINAR ON DEMAND: Why early matters: Data-driven strategies to de-risk OSD development
Late-stage surprises continue to drive cost, delay, and challenges in oral solid dosage (OSD) development—especially for complex, poorly soluble molecules. Too often, formulation and manufacturability risks surface only after significant time and investment.
In a recent panel discussion, GlobalData’s Director of Drugs Intelligence, Quentin Horgan, joins Thermo Fisher Scientific’s Senior Director of Global Technical and Scientific Affairs, Anil Kane, to explore how early insight can change the trajectory of OSD development.
This on-demand webinar focuses on how data-driven characterization, predictive modeling, and Quality by Design (QbD) approaches help teams identify and address risks earlier—when decisions are more flexible and impacts easier to manage, before scale-up begins.
Key takeaways:
- Why early development is a critical inflection point
Shift risk earlier to reduce cost, complexity, and late-stage surprises. - How data and predictive tools improve decisions
Reduce trial-and-error and enable smarter formulation and process choices. - What scalable OSD development looks like
Achieve smoother scale-up and more efficient paths to commercialization. - How the OSD market is evolving in 2026
Understand key trends, players, and growth across therapy areas.
Click to View the Webinar
Total Page Views: 99
